Del Monte Pacific (D03) Q2 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2026 earnings summary
21 Oct, 2026Executive summary
Q2 FY2026 continuing-operations sales rose 9.9% to US$234.9m, led by Asian markets and fresh pineapple exports.
Q2 net profit reached US$16.8m versus US$2.3m a year earlier; H1 net profit was US$22.3m.
U.S. operations were deconsolidated effective 1 May 2025, reducing consolidated liabilities by US$1.5bn.
Management expects profitable H2 growth, with increased investment and Philippine macroeconomic headwinds among the considerations.
Financial highlights
Q2 turnover was US$234.9m (+9.9%), gross profit US$80.4m (+36.5%) and EBITDA US$51.5m (+39.2%).
H1 turnover was US$438.6m (+11.3%), gross profit US$146.6m (+34.8%) and EBITDA US$90.7m (+26.2%).
Q2 gross margin expanded 660 bps to 34.2%; H1 gross margin rose 580 bps to 33.4%.
Q2 net margin improved to 7.2% from 1.1%; H1 net profit was US$22.3m versus US$2.7m.
H1 operating cash flow was US$162.7m, slightly lower year over year due to inventory buildup.
Outlook and guidance
Profitable growth is expected in H2 FY2026, barring unforeseen circumstances.
Priorities include Philippine market leadership, fresh-fruit leadership in North Asia, product launches, productivity, cost control and prudent capital management.
Fresh pineapple growth is supported by demand in China and Korea, quality focus, and secured land and supply through 2030.
Processed exports are expected to improve in H2 with better supply.
Latest events from Del Monte Pacific
- Net profit surged 192.6% on 9% higher sales, with restructuring underway to address negative equity.D03
Q1 2027 - Strong FY2026 growth and profitability, but negative equity restricts dividends.D03
Q4 2026 - Strong sales and margin gains offset U.S. exit, but negative equity and capital deficit persist.D03
Q3 2026 - Sales and margins rose, net profit reached US$5.5M; FY2026 profitability is expected.D03
Q1 2026 - Asian operations returned to profit after U.S. deconsolidation and impairment.D03
Q4 2025 - Sales up 4% but net loss widened to US$56m on higher costs and U.S. subsidiary challenges.D03
Q2 2025 - Sales up 4% year-over-year; net loss widened on US costs, but margin and turnaround efforts continue.D03
Q1 2025 - Net loss widened to $127m on flat sales; margin recovery and asset sales targeted in FY25.D03
Q4 2024 - Sales rose, but DMFC losses outweighed DMPI growth and widened the group loss.D03
Q3 2025